Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Outlook on the Inhalation Anesthesia Global Market to 2026 - by Product, Application, End-user and Region


DUBLIN, Dec. 2, 2021 /PRNewswire/ -- The "Inhalation Anesthesia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global inhalation anesthesia market exhibited moderate growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.

Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery. Some of the commonly used inhalation anesthetics include nitrous oxide, desflurane, isoflurane and sevoflurane. These anesthetics are administered using a laryngeal face airway and a tracheal tube connected to a vaporizer. They are highly effective in small doses and can induce respiratory depression, reduce the arterial blood pressure and increase cerebral blood flow when used in unmoderated quantities. In comparison to the traditionally used intravenous variants, inhalation anesthesia does not accumulate in the body and aids in preventing excessive dosage, while promoting normal functioning of the patient.

The increasing prevalence of chronic medical disorders requiring surgical treatments is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to ailments, such as cardiovascular, neurological, respiratory and degenerative disorders, is providing a thrust to the market growth. Hospitals and other ambulatory healthcare centers are widely using sevoflurane and other ether-based inhalation anesthetic agents with low pungency and non-irritant odor for patients with asthma or sensitive air passages.

Additionally, various technological advancements, such as the development of anesthesia recycling systems for extracting anesthetic compounds from hospital vents and operating rooms, are acting as other growth-inducing factors. In line with this, anesthesia manufacturers are also producing variants with enhanced compatibility and minimal side-effects to cater to the requirements of patients sensitive to anesthetic agents. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Inhalation Anesthesia Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Desflurane
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Sevoflurane
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Isoflurane
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast

7 Market Breakup by Application
7.1 Induction
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Maintenance
7.2.1 Market Trends
7.2.2 Market Forecast

8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ambulatory Surgical Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbvie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Baxter International Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Fresenius SE & Co. KGaA
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Halocarbon Products Corporation
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Hikma Pharmaceuticals PLC
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Lunan Pharmaceutical Group Co. Ltd
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Merck KGaA
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Piramal Enterprises Ltd.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Troikaa Pharmaceuticals Ltd
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/6o421d

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 05:31
Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, selective...

at 03:00
In 1825, John Quincy Adams signed a treaty that required Native Americans in Georgia to relinquish their claim on their land. It was a decision he regretted almost immediately, later declaring such policies to be "among the heinous sins of this...

22 jan 2022
POWERHANDZ is a global athletic training and rehabilitation product tech company transforming the way athletes and patients improve human performance through the combined use of smart sports products, technology and services for any stage of life....

22 jan 2022
Summary Brand(s): Searay Product: Sauerkraut Fish (Szechuan Style) Spicy Companies: Searay Foods Inc. Issue: Food ? Allergen ? Milk Category: Fish and seafood (Frozen) What to do: If you have an allergy to milk, do not consume the recalled product...

22 jan 2022
Summary Brand(s): Shirakiku Product: Baked Red Bean Cake Companies: Wismettac Asian Foods, Inc. Issue: Food ? Allergen ? Milk Category: Grain products What to do: If you have an allergy to milk, do not consume the recalled product Audience: General...

22 jan 2022
Natera, Inc. , a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American...



News published on 2 december 2021 at 12:45 and distributed by: